Logo image of CYCCP

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Fundamental Analysis

NASDAQ:CYCCP - Nasdaq - US23254L2079 - Currency: USD

4.06  -0.44 (-9.78%)

Premarket: 4 -0.06 (-1.48%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CYCCP. CYCCP was compared to 553 industry peers in the Biotechnology industry. While CYCCP seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CYCCP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CYCCP had negative earnings in the past year.
In the past year CYCCP has reported a negative cash flow from operations.
CYCCP had negative earnings in each of the past 5 years.
CYCCP had a negative operating cash flow in each of the past 5 years.
CYCCP Yearly Net Income VS EBIT VS OCF VS FCFCYCCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of CYCCP (-223.54%) is worse than 89.69% of its industry peers.
CYCCP's Return On Equity of -272.60% is on the low side compared to the rest of the industry. CYCCP is outperformed by 71.07% of its industry peers.
Industry RankSector Rank
ROA -223.54%
ROE -272.6%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYCCP Yearly ROA, ROE, ROICCYCCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYCCP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCCP Yearly Profit, Operating, Gross MarginsCYCCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

CYCCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CYCCP has been increased compared to 1 year ago.
CYCCP has more shares outstanding than it did 5 years ago.
CYCCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYCCP Yearly Shares OutstandingCYCCP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
CYCCP Yearly Total Debt VS Total AssetsCYCCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -169.64, we must say that CYCCP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -169.64, CYCCP is doing worse than 97.11% of the companies in the same industry.
CYCCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -169.64
ROIC/WACCN/A
WACC9.19%
CYCCP Yearly LT Debt VS Equity VS FCFCYCCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 5.60 indicates that CYCCP has no problem at all paying its short term obligations.
CYCCP has a Current ratio (5.60) which is in line with its industry peers.
A Quick Ratio of 5.60 indicates that CYCCP has no problem at all paying its short term obligations.
With a Quick ratio value of 5.60, CYCCP perfoms like the industry average, outperforming 58.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.6
Quick Ratio 5.6
CYCCP Yearly Current Assets VS Current LiabilitesCYCCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

CYCCP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.44%, which is quite impressive.
The Revenue for CYCCP has decreased by -96.86% in the past year. This is quite bad
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.98%
Revenue 1Y (TTM)-96.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 36.35% on average over the next years. This is a very strong growth
Based on estimates for the next years, CYCCP will show a very strong growth in Revenue. The Revenue will grow by 385.15% on average per year.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%

3.3 Evolution

CYCCP Yearly Revenue VS EstimatesCYCCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCCP Yearly EPS VS EstimatesCYCCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10K -20K -30K -40K -50K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYCCP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCCP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCCP Price Earnings VS Forward Price EarningsCYCCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCCP Per share dataCYCCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as CYCCP's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.20%, CYCCP is a good candidate for dividend investing.
The stock price of CYCCP dropped by -92.76% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
CYCCP's Dividend Yield is rather good when compared to the industry average which is at 106.17. CYCCP pays more dividend than 99.28% of the companies in the same industry.
CYCCP's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 6.2%

5.2 History

The dividend of CYCCP decreases each year by -37.25%.
CYCCP has been paying a dividend for over 5 years, so it has already some track record.
CYCCP has decreased its dividend recently.
Dividend Growth(5Y)-37.25%
Div Incr Years0
Div Non Decr Years1
CYCCP Yearly Dividends per shareCYCCP Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2 4 6 8

5.3 Sustainability

DP0%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
CYCCP Yearly Income VS Free CF VS DividendCYCCP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

More info and screens

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP

NASDAQ:CYCCP (7/31/2025, 8:15:38 PM)

Premarket: 4 -0.06 (-1.48%)

4.06

-0.44 (-9.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-12 2025-08-12
Inst Owners6.64%
Inst Owner Change-0.46%
Ins Owners61.46%
Ins Owner ChangeN/A
Market Cap6.41M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.2%
Yearly Dividend0.03
Dividend Growth(5Y)-37.25%
DP0%
Div Incr Years0
Div Non Decr Years1
Ex-Date07-21 2025-07-21 (0.15)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-47.71%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 458.2
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.09
EV/EBITDA N/A
EPS(TTM)-19.58
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-6.81
FCFYN/A
OCF(TTM)-6.81
OCFYN/A
SpS0.01
BVpS1.94
TBVpS1.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -223.54%
ROE -272.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.6
Quick Ratio 5.6
Altman-Z -169.64
F-Score3
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.98%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue 1Y (TTM)-96.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%
EBIT growth 1Y43.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y48.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.57%
OCF growth 3YN/A
OCF growth 5YN/A